How hyperlipidemia is tested on Step 1

Expect a patient with xanthomas, early MI, or recurrent pancreatitis and a lipid panel, and a question about the defective protein, inheritance, or drug of choice.

workspace_premium Match the sign to the lipid

Tendon xanthomas and corneal arcus point to high LDL. Eruptive xanthomas, milky plasma, and pancreatitis point to very high triglycerides.

Lipoprotein metabolism

Lipoproteins are defined by their apolipoproteins, which act as structural proteins, enzyme cofactors, and receptor ligands.

LivermakesVLDLApo B-100,triglyceridesLipoproteinlipaseRemoves TG(apo C-II)IDLHepaticlipaseLDLCholesterol-richLDLreceptorLiver,tissues takeit up
Endogenous pathway. PCSK9 promotes LDL receptor degradation; blocking it leaves more receptors to clear LDL.
ApolipoproteinFunctionLipoproteins
B-48Assembly and secretion of chylomicronsChylomicrons
B-100Binds LDL receptorVLDL, IDL, LDL
C-IIActivates lipoprotein lipaseChylomicrons, VLDL, HDL
EMediates remnant uptake by liverChylomicron remnants, VLDL, IDL, HDL
A-IActivates LCAT (cholesterol esterification)HDL

Lp(a) is LDL bound to apolipoprotein(a); high levels are an inherited cardiovascular risk factor.

Inherited dyslipidemias

Each disorder breaks a specific step.

Familial dyslipidemiasChylomicronemiaLPL or apo C-II; ↑↑TGFamilial highLDLLDL receptor, apoB-100, PCSK9; ↑↑ LDLRemnant diseaseApo E2; ↑chylomicron and VLDLremnantsHigh VLDLHepatic VLDLoverproduction; ↑ TG
Inherited dyslipidemias. Dysbetalipoproteinemia causes palmar xanthomas.
DisorderDefectInheritanceFindings
Familial chylomicronemia (type I)Lipoprotein lipase or apo C-II deficiencyAutosomal recessiveTG often > 1,000 mg/dL, pancreatitis, eruptive xanthomas, hepatosplenomegaly; no ↑ atherosclerosis
Familial hypercholesterolemia (type IIa)LDL receptor (or apo B-100, PCSK9 gain)Autosomal dominantHeterozygotes LDL ~200–400 mg/dL, homozygotes > 500; tendon xanthomas, MI before age 20 in homozygotes
Dysbetalipoproteinemia (type III)Apo E2 homozygosityAutosomal recessive (needs second hit)Palmar and tuberoeruptive xanthomas; premature vascular disease
Familial hypertriglyceridemia (type IV)Hepatic VLDL overproductionAutosomal dominantHigh TG; pancreatitis risk when severe

Homozygous familial hypercholesterolemia responds poorly to statins because receptors are absent; PCSK9 inhibitors also need functioning receptors.

Atherosclerosis and treatment

LDL particles enter the arterial intima, become oxidized, and are taken up by macrophages, forming foam cells and fatty streaks that mature into plaques.

High LDLAtherosclerosis, MI, strokeTendon xanthomas, xanthelasmaCorneal arcus (young age)First-line: statinAdd ezetimibe, PCSK9 inhibitorVery high triglyceridesAcute pancreatitis (TG > 1,000)Eruptive xanthomasLipemia retinalis, milky plasmaFirst-line: fibrateOmega-3s; treat diabetes, alcoholvs
LDL vs triglycerides. Statins also lower triglycerides modestly and reduce cardiovascular events most.
DrugTarget stepMain lipid effect
StatinsHMG-CoA reductase β†’ ↑ LDL receptors↓↓↓ LDL
EzetimibeNPC1L1 intestinal cholesterol absorption↓ LDL
PCSK9 inhibitorsPrevent LDL receptor degradation↓↓↓ LDL
FibratesPPAR-Ξ± β†’ ↑ lipoprotein lipase↓↓↓ TG
Omega-3 fatty acids↓ Hepatic VLDL production↓ TG
Bile acid sequestrantsBind bile acids β†’ liver uses cholesterol↓ LDL (↑ TG)

See the statin guide for intensity tiers, myopathy, and interactions.

Clinical application

Physical signs plus family history often make the diagnosis.

functions Worked example β€” the knuckle nodules

A 34-year-old man has firm nodules on his Achilles tendons and knuckle extensor tendons. His father died of an MI at 42. LDL is 310 mg/dL; triglycerides are normal. What is the defect, and what is first-line therapy?

  1. Tendon xanthomas with markedly elevated LDL and early family MI suggest familial hypercholesterolemia.
  2. Heterozygous LDL receptor mutations halve LDL clearance; inheritance is autosomal dominant.
  3. Statins upregulate the remaining functional receptors.

Answer. Heterozygous familial hypercholesterolemia (LDL receptor defect). Start a high-intensity statin, add ezetimibe and a PCSK9 inhibitor as needed, and screen first-degree relatives.